Studies from Fourth Hospital of Hebei Medical University Add New Findings in the Area of Non-Small Cell Lung Cancer [The Mrna of Solute Carrier Family 22, Member 17 (Slc22a17) Plays the Potential Diagnostic and Prognostic Role In Advantage...].
In: Cancer Weekly, 2024-04-16, S. 1249-1249
serialPeriodical
Zugriff:
A study conducted at the Fourth Hospital of Hebei Medical University in China aimed to evaluate the potential diagnostic and prognostic value of solute carrier family 22, member 17 (SLC22A17) mRNA levels in non-small cell lung cancer. The study found that SLC22A17 mRNA levels were significantly higher in lung cancer samples compared to paired paracancerous tissues. Additionally, plasma SLC22A17 mRNA levels were significantly higher in lung cancer patients compared to healthy controls. The study concluded that SLC22A17 may serve as a novel diagnostic and prognostic biomarker for lung cancer. [Extracted from the article]
Copyright of Cancer Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Studies from Fourth Hospital of Hebei Medical University Add New Findings in the Area of Non-Small Cell Lung Cancer [The Mrna of Solute Carrier Family 22, Member 17 (Slc22a17) Plays the Potential Diagnostic and Prognostic Role In Advantage...].
|
---|---|
Zeitschrift: | Cancer Weekly, 2024-04-16, S. 1249-1249 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1071-7218 (print) |
Sonstiges: |
|